Bobak Azamian

Bobak Azamian co-founded Tarsus Pharmaceuticals, Inc. with Michael Ackermann in November 2016 and has served as its President and CEO since September 2018. He has served as the company’s Chairman since December 2022. Since its founding, Tarsus has established a leading team and culture and has completed successful fundraising efforts through multiple private and public financings and global partnerships. Tarsus recently secured FDA approval for its first product, XDEMVY™ (lotilaner ophthalmic solution) 0.25%, which is the first and only FDA-approved treatment in the United States for the eyelid disease Demodex blepharitis. Beyond XDEMVY, Tarsus continues to advance its pipeline into Phase 2 clinical studies evaluating therapies that have the potential to create new categories to treat other major diseases, including meibomian gland disease, rosacea and Lyme disease prevention.

Azamian has co-founded and led other novel therapeutics companies Vibrato Medical and Metavention, and currently serves on the board of Vibrato Medical and as Chairman of the board of Osanni Bio. Azamian began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer for a variety of life sciences companies. He also served on the board of the nonprofit organization Octane.

Azamian trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women’s Hospital. He received an MD from Harvard Medical School (Harvard-MIT Heath Sciences and Technology), a PhD in chemistry from Oxford University as a Rhodes Scholar, and a BA in physics from Rice University. He is also an author of numerous patents and peer-reviewed publications.